Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
113,017
Sort by:
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Global Protein Therapeutics Market Analysis
US$ 1,800.00
Single User PDF Format: US$ 1,800.00
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00 Within the global pharmaceutical industry, protein therapeutics has b...
July 2011
180 pages
US e-health Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00 The US represents one of the most developed healthcare markets global...
July 2011
75 pages
Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors
US$ 275.00
... The present Competitive Intelligence report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules ... database will be sent by e-mail and allow online work with the project data to print or export an individual report. Inhibition of heat shock ...
July 2011
26 pages
Competitor Analysis: HDAC Inhibitors
US$ 550.00
... the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Histone deacetylase (HDAC) ... class I and II Inhibitors Multi-Target HDAC Inhibitors Others Corporate HDAC Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The ...
July 2011
58 pages
Regeneron - Entering the Commercial TRAP
US$ 140.00
... US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the ...
July 2011
7 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Novartis vs. Peer group- Growth rate differential to widen going forward
US$ 90.00
Novartis reported solid revenue growth driven by Sandoz, recently launched products and Alcon Acquisition. Going ... shape up in the longer term. Novartis is in better position to return back profits to investors compare to its global peers in unfavorable environment mainly due to its ...
July 2011
2 pages
Mixed CARE-MS I data – Good for BIIB!
US$ 90.00
... (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players ... ? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
July 2011
4 pages
Mirabegron Gets JP Approval – Expecting US Filing & Approval In Time!
US$ 90.00
... rating on Astellas following announcement of JP approval for Betanis / mirabegron (β3-AR agonist, overactive bladder syndrome (OAB). Mirabegron is a key strategic product for ... able to maintain its leadership in the growing OAB market. Mirabegron will be targeted for those patients who are intolerant to ...
June 2011
4 pages
NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
US$ 90.00
... daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once ... antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately ...
June 2011
2 pages
Eliquis (Apixaban) meets endpoints in ARISTOTLE - Stock Price Reaction premature
US$ 140.00
... from the ARISTOTLE trial, Eliquis met both, the primary (reduction in stroke and embolism) and secondary endpoint (reduction in major bleeding and ... stock price reaction is a bit premature, as detailed data is crucial to understand Eliquis relative efficacy/safety compared to Pradaxa and Xarelto. From a trial ...
June 2011
3 pages
REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout
US$ 90.00
... ) or colchicine primarily on safety concerns. Based on our analysis, we reiterate our Outperform rating on Regeneron (REGN) with a revised TP of $62 (vs. previous $65) as we believe both these drugs ... read our report released on 23rd June, 2011 on REGN named “Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout”.
June 2011
5 pages
World Wound Care Markets 2011
US$ 2,995.00
Prices: Single User PDF: US$ 2,995.00 Departmental Site License (one location, up to 10 users): US$ 4,400.00 Global Site License: US$ 5,990.00 The wound care industry is an highly diverse and compet...
June 2011
175 pages
Israel Life Sciences Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 The field of life sciences has stipulated itself as one of the major businesses in Israel....
June 2011
55 pages
MSL-KOL Engagement: Ensuring Compliance
US$ 495.00
After its initial function to build rapport with KOLs, the MSL role has evolved from being a support to sales reps to the forefront of pharmaceutical practice. Lode Dewulf, chief medical affairs offic...
June 2011
47 pages
What Consumers Want – Buying Trends in European Home Care
US$ 2,000.00
... consumer purchasing patterns today and in the future. Euromonitor International's What Consumers Want – Buying Trends in European Home Care global briefing offers an ... and forecasts), company shares, brand shares and distribution data. Why buy this report? Get a detailed picture of the Home Care market; ...
June 2011
43 pages
Global Wound Care Market Report: 2011 Edition
US$ 700.00
... reliability, price, and global reach, among such other factors. The report offers an analysis of the global wound care market. It also discusses key market trends, growth drivers ...
June 2011
34 pages
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
US$ 660.00
... other pathywas such as the PI3K-Akt-mTOR pathways. Combining a mutant B-Raf inhibitor with a targeted T-cell antibody, such as ipilimumab, may increase ... ERK Pathway Corporate Ras-Raf-MEK-ERK Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...
June 2011
75 pages
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
US$ 711.00
... effort has gone into developing agents that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as closely related proteins implicated in ... Others Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...
June 2011
100 pages
Competitor Analysis: IGF-1R Antagonists
US$ 275.00
... -1/R antagonists Small Molecule Multi-target IGF-1/R antagonists Biologics as Selective IGF-1/R antagonists Biologics as Dual IGF-1/R antagonists Corporate IGF-1R Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
June 2011
26 pages
INTERCELL - No Tangible Value!
US$ 90.00
... on sideline, as there is no catalyst in 2011-12 that could boost the stock. Intercell (ICLL) woes of 2010 became worse in 2011 chiefly due to the ...
June 2011
1 pages
Catalysts Driven Investment Opportunities
US$ 140.00
... ) in the Biotech sector. The table lists the drug related catalysts for the Rising Star or Mature Biotech companies, our expectations ... of the series, which we will keep releasing in a timely manner. The catalysts include outcome of Advisory Committee Meetings (only June), PDUFA dates ...
June 2011
4 pages
Dr Reddy's PARA IV Pipeline Analysis
US$ 350.00
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), ... Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
June 2011
21 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
Lupin has pipeline of ~34 products having branded sales of ~$16b. Among its Para IV pipeline most lucrative opportunities are very few like that of Geodon, ... and Asacol. On other hand there are some Para IVs ...
June 2011
28 pages
Para IV presentation
US$ 350.00
A macro study on Indian Pharma Para IV litigations – a part of our recently introduced web based application - PARA IV Plus™ . This will provide you with a broad but meaningful insight to the prevalence of Indian Pharmaceutical companies in the Para IV space
June 2011
9 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
DISHMAN - Back To Basics
US$ 90.00
We reiterate our Underperform rating on Dishman despite it’s higher than expected Q4 FY11 result. The result was ...
May 2011
5 pages
Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline
US$ 140.00
... for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has ... ), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180 ... all other generics as well. We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) ...
May 2011
2 pages
China Health Management Survey Report, 2011
US$ 1,400.00
With the development of Chinese economy, improvement of living standards and intensified aging population, Chinese people have growing demand for health management. In China, many industries are activ...
May 2011
62 pages
Market Access Europe: It's Not Just About Price
US$ 795.00
“May you live in interesting times.” Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe. Given its complex geo-po...
May 2011
71 pages
Medicated Skin Care in Kazakhstan
US$ 990.00
... on high-priced medicines, such as medicated skin care. Changing perceptions of beauty have also made people less... Euromonitor International's Medicated Skin Care in Kazakhstan report offers a comprehensive guide ... and Allergy Remedies, Child-Specific Digestive Remedies, Child-Specific Medicated Skin Care, Cold Sore Treatments, Combination Products - Cough, Cold and Allergy ...
May 2011
24 pages
Healthcare IT Market in Emerging Economies (2010 - 2015)
US$ 5,650.00
... quality healthcare delivery by growing aging population, and increase in chronic disease patient population is driving the increased adoption of IT solutions in the emerging markets. The Healthcare IT markets in emerging economies is expected to grow from $5.3 billion in 2010 to $10.9 billion in 2015, at an estimated CAGR of 15.3% from 2010 to 2015. The hardware segment dominates the healthcare IT market in emerging ...
May 2011
259 pages
